Search
Zymeworks Inc
ZYMEAdd to Watchlist
23.260USD
+0.120+0.52%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
1.75BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Zymeworks Inc is 8.57, ranking 100 out of 389 in the Biotechnology & Medical Research industry. The average price target is 33.50, with a high of 42.00 and a low of 25.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
39.231
Target Price
+69.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Zymeworks Inc
ZYME
14
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Zymeworks Inc's expected revenue for the next quarter?
Zymeworks Inc's expected revenue is 18.71M.
What is Zymeworks Inc's price target?
Analysts forecast that Zymeworks Inc's price target is USD 33.50, with the highest forecast at USD 42.00 and the lowest forecast at USD 25.00.
How have Zymeworks IncZYME's recent earnings per share performed?
The market expectation was USD -0.59, while Zymeworks IncZYME's earnings per share (EPS) for the previous quarter was USD -0.55. EPS for the next quarter is expected at USD -0.42.
What is the analyst rating for Zymeworks Inc?
Based on the ratings of Zymeworks Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
